Professor Jenette Creaney



Professor Creaney is the Head of the Biomarkers and Discovery unit of NCARD. The group is investigating biomarkers for improved diagnosis and monitoring of patients with mesothelioma and also examining the use of biomarkers for screening asbestos-exposed individuals for early detection of mesothelioma.

Jenette received her PhD in 1995 from La Trobe University (Melbourne, Australia), and has worked in the cancer and immunology fields as a molecular biologist and protein chemist since. Jenette returned to Australia from the US in 1999 to work with Professor Bruce Robinson in Perth, on principally the marker discovery projects. The work from the group includes the seminal work on the biomarker mesothelin for use in patients with mesothelioma.

Jenette has received several prestigious awards for her work in Science including the Howard Hughes Medical Institute Postdoctoral Fellowship and a Young Investigator Award.



  • PhD candidate Amber Louw was awarded a research scholarship from the icare NSW Dust Diseases Board
  • Best Poster Prize at the International Mesothelioma Conference, Ottawa, Canada, “Whole genome sequencing of malignant mesothelioma”.


  • Chee J, Robinson BW, Holt RA, Creaney J. Immunotherapy of lung malignancies – from gene sequencing to novel therapies. Chest. 2017 151:891-897 PMID: 27769776
  • Creaney J, Robinson BW. Malignant mesothelioma biomarkers – from discovery to use in clinical practise for diagnosis, monitoring, screening and treatment. Chest. 2017 152:143-149 PMID: 28007619
  • Hmeljak J, Sanchez-Vega F, Hoadley KA, Shih J, Stewart C, Heiman D, Tarpey P, Danilova L, Drill E, Gibb EA, Bowlby R, Kanchi R, Osmanbeyoglu HU, Sekido Y, Takeshita J, Newton Y, Graim K, Gupta M, Gay CM, Diao L, Gibbs DL, Thorsson V, Iype L, Kantheti H, Severson DT, Ravegnini G Desmeules P, Jungbluth AA, Travis WD, Dacic S, Chirieac LR, Galateau-Sallé F, Fujimoto J, Husain AN, Silveira HC, Rusch VW, Rintoul RC, Pass H, Kindler H, Zauderer MG, Kwiatkowski DJ, Bueno R, Tsao AS, Creaney J, Lichtenberg T, Leraas K, Bowen J; TCGA Research Network, Felau I, Zenklusen JC, Akbani R, Cherniack AD, Byers LA, Noble MS, Fletcher JA, Robertson AG, Shen R, Aburatani H, Robinson BW, Campbell P, Ladanyi M. Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discovery. 2018 8:1548-1565 PMID: 30322867
  • Creaney J, Dick IM, Leon JS, Robinson BW. A proteomic analysis of the malignant mesothelioma secretome using iTRAQ. Cancer Genomics Proteomics. 2017 14:103-117 PMID: 28387650
  • Sneddon S, Patch A-M, Dick IM, Kazakoff S, Pearson JVP, Waddell N, Allcock RJN, Holt RA, Robinson BWS & Creaney J. Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma. BMC Cancer 2017 17:396-405. PMID: 28577549
  • Sneddon S, Dick I, Lee YCG, Musk AWB, Patch AM, Pearson JV, Waddell N, Allcock RJN, Holt RA, Robinson BWS, Creaney J. Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations. Lung Cancer. 2018 119:64-70. PMID: 2965675
  • Fear VS, Forbes CA, Chee J, Ma S, Neeve S, Celliers L, Fisher SA, Dick I, Creaney J, Robinson BWS. Neo-antigen specific T cell responses indicate the presence of metastases before imaging. Scientific  Reports 2019 9:14640. PMID: 31601975
  • Ma S, Chee J, Fear VS, Forbes CA, Boon L, Dick IM, Robinson BWS, Creaney J. Pre-treatment tumor neo-antigen responses in draining lymph nodes are infrequent but predict checkpoint blockade therapy outcome. Oncoimmunology 2019; 9: 1684714. PMID: 32002299
  • Sneddon S, Rive CM, Ma S, Dick IM, Allcock RJN, Brown SD, Holt RA, Watson M, Leary S, Lee YCG, Robinson BWS, Creaney J. Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma. Oncoimmunology 2020; 9: 1684713. PMID: 32002298